Market Overview

UPDATE: Morgan Stanley Raises PT on Baxter International on Neutral Risk-Reward

Share:
Related BAX
Earnings Scheduled For April 23, 2015
Baxter's BioScience Unit Announces Positive Phase III Results for BAX 817
Akorn Downgraded, Stock Falls On 'Credibility Gap' (Investor's Business Daily)

In a report published Monday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating on Baxter International (NYSE: BAX), and raised the price target from $71.00 to $84.00.

In the report, Lewis noted, “We see a neutral risk-reward into Baxter's highly-anticipated PIII Alzheimer's data. We estimate the stock price currently includes roughly $3-5 in AD optionality, placing likely downside at 3-10% for a total failure (missed primary endpoints, missed subgroup analyses). Upside in the unlikely (p=5%) case of success on both primary endpoints could be $6-11, or 8-15%. Several intermediate cases of mixed results or suggestive subgroup analyses could drive less extreme outcomes and will likely punt investment implications until the presentation of full data results.”

Baxter International closed on Friday at $70.94.

Latest Ratings for BAX

DateFirmActionFromTo
Apr 2015BMO CapitalMaintainsOutperform
Apr 2015JP MorganMaintainsNeutral
Feb 2015JP MorganMaintainsNeutral

View More Analyst Ratings for BAX
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Price Target Analyst Ratings

 

Related Articles (BAX)

Around the Web, We're Loving...